TRAVERE THERAPEUTICS, INC. Cash and Restricted Cash
TRAVERE THERAPEUTICS, INC. (TVTX) had Cash and Restricted Cash of $117.73 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $117.73M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.36M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $93.03M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $110.93M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $117.73M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $78.36M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $93.03M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $110.93M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $75.15M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $61.90M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $58.53M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $36.41M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $32.29M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $43.25M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $58.18M 10-K · filed 2026-02-19 |
| 2023-09-30 | $144.24M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $70.87M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $161.38M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $61.69M 10-K · filed 2026-02-19 |
| 2022-09-30 | $151.34M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $179.76M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $256.57M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $165.75M 10-K · filed 2025-02-21 |
| 2021-09-30 | $150.33M 10-Q · filed 2022-10-27 |
| 2021-06-30 | $83.29M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $148.23M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $84.77M 10-K · filed 2024-02-20 |
| 2020-09-30 | $200.48M 10-Q · filed 2021-10-29 |
| 2020-06-30 | $237.17M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $67.02M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $62.44M 10-K · filed 2023-02-23 |
| 2019-09-30 | $65.19M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $75.66M 10-Q · filed 2020-07-31 |
| 2019-03-31 | $69.84M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $102.87M 10-K · filed 2022-02-24 |
| 2018-09-30 | $154.82M 10-Q · filed 2019-10-30 |
| 2018-06-30 | $89.31M 10-Q · filed 2019-08-06 |
| 2018-03-31 | $61.12M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $99.39M 10-K · filed 2021-03-01 |
| 2016-12-31 | $41.00M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |